Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Receives Aetna Coverage for VeriStrat Lung Cancer Test

NEW YORK (GenomeWeb) – Biodesix said today that its has received a positive coverage decision from Aetna for its VeriStrat test for guiding therapy in patients with non-small cell lung cancer (NSCLC).

According to Biodesix, Aetna has deemed VeriStrat, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors, medically necessary for patients with advanced NSCLC whose tumors were without EGFR and anaplastic lymphoma kinase mutations.

Aetna has approximately 46 million members in the US.

The decision comes just days after Biodesix announced that Cigna had agreed to cover VeriStrat, and follows similar decisions by UnitedHealthcare and CareFirst Blue Cross Blue Shield in recent months.